The researchers found that among subclasses, IgG1 expression was most prominent in samples from patients with multiple myeloma, and expression of IgG1 changed significantly before, throughout, and ...

Robert Orlowski, MD, PhD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses prophylactic ...

TORONTO -- A substantial proportion of multiple myeloma patients undergoing treatment with bispecific antibodies had sustained remissions when they discontinued therapy before disease progression, ...

Fifteen percent of patients with myeloma did not have detectable antibodies two weeks after receiving the COVID-19 vaccine. Patients with multiple myeloma had suboptimal antibody response against ...

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...

Your doctor tells you your multiple myeloma is in remission. But what exactly does that mean? The first thing to understand is that being in remission is not the same thing as being cured. The ...